Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 37, 2009, Pages 15956-15960

  Carbrey, Jennifer M ^a   Song, Linhua ^a   Zhou, Yao ^b,c   Yoshinaga, Masafumi ^b,c   Rojek, Aleksandra ^d   Wang, Yiding ^a   Liu, Yangjian ^a   Lujan, Heidi L ^c   DiCarlo, Stephen E ^c   Nielsen, Søren ^d   Rosen, Barry P ^b,c   Agre, Peter ^a,e   Mukhopadhyay, Rita ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AARHUS UNIVERSITY   (Denmark)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAGLYCEROPORIN 9; ARSENATE SODIUM; ARSENIC; CARRIER PROTEIN; ELECTROLYTE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASOLATERAL MEMBRANE; BRADYCARDIA; CONTROLLED STUDY; ELECTROLYTE BLOOD LEVEL; FECES ANALYSIS; HEART; IMMUNOHISTOCHEMISTRY; KIDNEY; LD 50; LIVER; LIVER CELL; LIVER CLEARANCE; LIVER SINUSOID; LUNG; MOUSE; MOUSE STRAIN; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLEEN; SURVIVAL RATE; TESTIS; TISSUE LEVEL; URINE LEVEL; WILD TYPE;

ANIMALS; AQUAPORINS; ARSENIC; ARSENITES; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; IMMUNOHISTOCHEMISTRY; LETHAL DOSE 50; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; SODIUM COMPOUNDS; TISSUE DISTRIBUTION;

ANIMALIA; MUS;

EID: 70349471282     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0908108106     Document Type: Article

References (34)

1. Kinniburgh DG, Smedley PL (2001) Arsenic Contamination of Groundwater in Bangladesh (British Geological Survey, Keyworth, UK), pp 231-255.
2. Tallman MS (2008) The expanding role of arsenic in acute promyelocytic leukemia. Semin Hematol 45:S25-S29.
3. Hu J, et al. (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 106:3342-3347.
4. Borst P, Ouellette M (1995) New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 49:427-460.
5. Huang RN, Lee TC (1996) Arsenite efflux is inhibited by verapamil, cyclosporin A, and GSH-depleting agents in arsenite-resistant Chinese hamster ovary cells. Toxicol Appl Pharmacol 141:17-22.
6. Vernhet L, Allain N, Bardiau C, Anger JP, Fardel O (2000) Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals. Toxicology 142:127-134.
7. Lee TC, Ho IC, Lu WJ, Huang JD (2006) Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J Biol Chem 281:18401-18407.
8. Lorico A, et al. (1997) Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 57:5238-5242. (Pubitemid 27516355)
9. Liu J, Liu Y, Powell DA, Waalkes MP, Klaassen CD (2002) Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 170:55-62. (Pubitemid 34031864)
10. Wysocki R, et al. (2001) The glycerol channel Fps1p mediates the uptake of arsenite and antimonite in Saccharomyces cerevisiae. Mol Microbiol 40:1391-1401. (Pubitemid 32635307)
11. Liu Z, et al. (2002) Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci USA 99:6053-6058. (Pubitemid 34493263)
12. Bhattacharjee H, Carbrey J, Rosen BP, Mukhopadhyay R (2004) Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun 322:836-841. (Pubitemid 39164428)
13. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW (2007) Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 109:740-746. (Pubitemid 46105976)
14. Miao ZF, et al. (2009) Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells. Toxicol In Vitro 23:209-216.
15. Shinkai Y, Sumi D, Toyama T, Kaji T, Kumagai Y (2009) Role of aquaporin 9 in cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes. Toxicol Appl Pharmacol 237:232-236.
16. Tsukaguchi H, et al. (1998) Molecular characterization of a broad selectivity neutral solute channel. J Biol Chem 273:24737-24743. (Pubitemid 28454975)
17. Liu Z, Styblo M, Rosen BP (2006) Methylarsonous acid transport by aquaglyceroporins. Environ Health Perspect 114:527-531.
18. Ishibashi K, et al. (1998) Cloning and functional expression of a new aquaporin (AQP9) abundantly expressed in the peripheral leukocytes permeable to water and urea, but not to glycerol. Biochem Biophys Res Commun 244:268-274. (Pubitemid 28419937)
19. Elkjaer M, et al. (2000) Immunolocalization of AQP9 in liver, epididymis, testis, spleen, and brain. Biochem Biophys Res Commun 276:1118-1128.
20. Winski SL, Carter DE (1995) Interactions of rat red blood cell sulfhydryls with arsenate and arsenite. J Toxicol Environ Health 46:379-397.
21. Crecelius EA (1977) Changes in the chemical speciation of arsenic following ingestion by man. Environ Health Perspect 19:147-150.
22. Lerman S, Clarkson TW (1983) The metabolism of arsenite and arsenate by the rat. Fundam Appl Toxicol 3:309-314.
23. Kala SV, et al. (2000) The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275:33404-33408.
24. Carbrey JM, et al. (2003) Aquaglyceroporin AQP9: Solute permeation and metabolic control of expression in liver. Proc Natl Acad Sci USA 100:2945-2950.
25. Carbrey JM, Agre P (2009) Discovery of the aquaporins and development of the field. Handb Exp Pharmacol 190:23-28.
26. Liu Y, et al. (2007) Aquaporin 9 is the major pathway for glycerol uptake by mouse erythrocytes, with implications for malarial virulence. Proc Natl Acad Sci USA 104:12560-12564.
27. Li C, et al. (2005) Distribution of aquaporin-9 in the rat:Animmunohistochemical study. Int J Tissue React 27:51-58.
28. Shen ZX, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
29. Huang SY, et al. (1998) Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 103:1092-1095.
30. Chiang CE, Luk HN, Wang TM, Ding PY (2002) Prolongation of cardiac repolarization by arsenic trioxide. Blood 100:2249-2252.
31. Ficker E, et al. (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44.
32. Rojek AM, et al. (2007) Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc Natl Acad Sci USA 104:3609-3614.
33. Figarella K, et al. (2007) Biochemical characterization of Leishmania major aquaglyceroporin LmAQP1: Possible role in volume regulation and osmotaxis. Mol Microbiol 65:1006-1017.
34. Cui X, Kobayashi Y, Hayakawa T, Hirano S (2004) Arsenic speciation in bile and urine following oral and intravenous exposure to inorganic and organic arsenics in rats. Toxicol Sci 82:478-487.